Cessatech Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 0/6
Cessatech's earnings have been declining at an average annual rate of -48.9%, while the Pharmaceuticals industry saw earnings growing at 8.4% annually.
Key information
-48.9%
Earnings growth rate
2.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 30.5% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Cessatech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -27 | 23 | 0 |
| 30 Sep 23 | 0 | -22 | 24 | 0 |
| 30 Jun 23 | 0 | -18 | 22 | 0 |
| 31 Mar 23 | 0 | -16 | 20 | 0 |
| 31 Dec 22 | 0 | -15 | 18 | 0 |
| 30 Sep 22 | 0 | -13 | 22 | 0 |
| 30 Jun 22 | 0 | -13 | 20 | 0 |
| 31 Mar 22 | 0 | -12 | 17 | 0 |
| 31 Dec 21 | 0 | -12 | 14 | 0 |
Quality Earnings: CESSA is currently unprofitable.
Growing Profit Margin: CESSA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if CESSA's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare CESSA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CESSA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.2%).
Return on Equity
High ROE: CESSA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.